Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

NOVATO, Calif., Jan. 04, 2024 -- Ultragenyx Pharmaceutical Inc. today announced that the National Institute for Health and Care Excellence has issued a final draft guidance recommending Evkeeza®...

Related Keywords

Germany ,United States ,Italy ,Canada ,United Kingdom ,Joshua Higa ,Jules Payne ,Erik Harris ,Jaimini Cegla ,Carolyn Wang ,European Union ,National Institute For Health ,Ultragenyx Pharmaceutical Inc ,Nasdaq ,Linkedin ,Regeneron Pharmaceuticals Inc ,Cardiovascular Risk Service ,Exchange Commission ,Regulatory Agency ,National Institute ,Care Excellence ,Heart United ,Homozygous Familial Hypercholesterolemia ,Nonproprietary Naming ,Biological Products Guidance ,Forward Looking Statements ,Private Securities Litigation Reform Act ,Quarterly Report ,Investor Relations ,Markets ,